Teachers Retirement System of The State of Kentucky cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 27.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,664 shares of the company’s stock after selling 18,322 shares during the quarter. Teachers Retirement System of The State of Kentucky owned 0.05% of Neurocrine Biosciences worth $3,698,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently made changes to their positions in NBIX. Dimensional Fund Advisors LP lifted its position in Neurocrine Biosciences by 6.5% during the second quarter. Dimensional Fund Advisors LP now owns 176,197 shares of the company’s stock valued at $8,105,000 after purchasing an additional 10,782 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares during the last quarter. Nationwide Fund Advisors lifted its position in Neurocrine Biosciences by 3.2% during the third quarter. Nationwide Fund Advisors now owns 124,351 shares of the company’s stock valued at $7,620,000 after purchasing an additional 3,800 shares during the last quarter. Crossmark Global Holdings Inc. bought a new stake in Neurocrine Biosciences during the third quarter valued at approximately $286,000. Finally, American Century Companies Inc. lifted its position in Neurocrine Biosciences by 7.2% during the third quarter. American Century Companies Inc. now owns 36,148 shares of the company’s stock valued at $2,215,000 after purchasing an additional 2,443 shares during the last quarter.
Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $87.92 on Friday. The company has a quick ratio of 10.20, a current ratio of 10.20 and a debt-to-equity ratio of 0.99. Neurocrine Biosciences, Inc. has a one year low of $39.21 and a one year high of $92.98. The company has a market cap of $8,189.06, a price-to-earnings ratio of -53.61 and a beta of 0.31.
In related news, insider Haig P. Bozigian sold 1,625 shares of Neurocrine Biosciences stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $79.12, for a total value of $128,570.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock in a transaction on Thursday, December 28th. The stock was sold at an average price of $75.00, for a total transaction of $1,142,775.00. Following the completion of the transaction, the insider now directly owns 28,394 shares in the company, valued at $2,129,550. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 399,589 shares of company stock worth $32,443,795. 4.80% of the stock is owned by insiders.
Several research analysts have commented on NBIX shares. Oppenheimer set a $85.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Tuesday, December 12th. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. Jefferies Group lifted their price target on shares of Neurocrine Biosciences to $105.00 and gave the stock a “buy” rating in a research note on Friday, January 5th. Needham & Company LLC lifted their price target on shares of Neurocrine Biosciences to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Finally, Barclays reissued an “overweight” rating and set a $100.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, February 14th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $95.23.
WARNING: This story was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://stocknewstimes.com/2018/03/17/neurocrine-biosciences-inc-nbix-shares-sold-by-teachers-retirement-system-of-the-state-of-kentucky.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.